Does Aetna Cover Trulicity?

Aetna's Formulary Placement for Trulicity

Aetna includes dulaglutide (Trulicity) on the majority of its commercial, Medicare Advantage, and managed Medicaid formularies. The drug sits on either the preferred brand (Tier 3) or non-preferred brand (Tier 4) level depending on the specific plan purchased by your employer or selected during open enrollment.

Formulary placement matters because it determines your cost-sharing. Aetna negotiates rebates with manufacturers, and the resulting preferred or non-preferred status directly affects your copay or coinsurance percentage. On Aetna's 2025-2026 national preferred drug lists, Trulicity appears alongside other GLP-1 receptor agonists like semaglutide (Ozempic) and liraglutide (Victoza), though the preferred position between these drugs shifts annually based on rebate negotiations [1].

Aetna's clinical policy bulletins classify GLP-1 receptor agonists as "medically necessary" for adults with type 2 diabetes who meet specific criteria. The American Diabetes Association Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin, or as first-line therapy in patients with established atherosclerotic cardiovascular disease (ASCVD) [2]. Aetna's coverage criteria align closely with these ADA guidelines.

Your specific plan documents (the Summary of Benefits and Coverage, or SBC) are the final word on tier placement. Two Aetna members at different employers can have different copays for the same drug. Check your plan's formulary at Aetna's online drug lookup tool or call the number on your member ID card.

Prior Authorization Requirements

Nearly every Aetna plan requires prior authorization (PA) before covering Trulicity. This is standard across the insurance industry for GLP-1 receptor agonists, not unique to Aetna.

Aetna's PA criteria for dulaglutide typically require documentation of the following: a confirmed diagnosis of type 2 diabetes mellitus, a recent HbA1c value (usually 7.0% or higher despite current therapy), trial and failure of metformin (or a documented contraindication to metformin), and prescribing by or in consultation with an endocrinologist or the patient's primary care provider [3]. The Endocrine Society's clinical practice guidelines support GLP-1 RA use when glycemic targets are not met with first-line agents, which forms the clinical basis for these PA requirements.

The PA process works like this. Your prescriber submits a request to Aetna (electronically through the pharmacy benefits manager or by fax). Aetna reviews the request against its clinical criteria. A decision is typically returned within 72 hours for standard requests and 24 hours for urgent requests. If approved, the authorization is valid for 12 months on most Aetna plans before renewal is needed.

Denials happen. Common reasons include insufficient documentation of metformin failure, missing lab values, or the prescriber not providing enough clinical rationale. A clean, complete submission on the first attempt dramatically improves approval rates.

Step Therapy: What Aetna Requires Before Approving Trulicity

Step therapy is the requirement that you try (and fail) a less expensive medication before your insurer will cover a more costly one. Aetna applies step therapy protocols to most GLP-1 receptor agonists, including Trulicity.

The typical step therapy sequence for Aetna looks like this: metformin (first-line, 3-month trial), then a sulfonylurea or SGLT2 inhibitor (second-line on some plans), and then a GLP-1 receptor agonist like Trulicity. Some Aetna plans skip the sulfonylurea step entirely, requiring only documented metformin use before GLP-1 approval [4].

The ADA's 2024 Standards of Care actually recommend skipping directly to a GLP-1 RA (bypassing sulfonylureas) for patients with ASCVD, heart failure, or chronic kidney disease [2]. This creates an important exception. If your patient has cardiovascular comorbidities, your prescriber can request a step therapy override by citing ADA guidelines and the REWIND trial, which demonstrated that dulaglutide reduced major adverse cardiovascular events (MACE) by 12% versus placebo in 9,901 participants with type 2 diabetes over a median 5.4-year follow-up (HR 0.88 to 95% CI 0.79-0.99) [5].

Metformin intolerance is another valid override. Gastrointestinal side effects affect roughly 20-30% of patients started on metformin according to data published in Diabetes Care [6]. If your prescriber documents GI intolerance (even with extended-release formulations), Aetna should approve the step therapy exception.

What Trulicity Costs with Aetna Insurance

Your out-of-pocket cost depends on three variables: your plan's tier placement for Trulicity, whether you have a copay or coinsurance structure, and whether you have met your deductible.

For Aetna commercial plans with copay structures, Trulicity typically costs $25 to $75 per month when placed on a preferred brand tier and $75 to $150 per month on a non-preferred brand tier. Plans with coinsurance structures charge a percentage of the drug's negotiated cost. That is usually 20-40%, which can mean $100 to $250 per fill before the out-of-pocket maximum is reached.

High-deductible health plans (HDHPs) paired with Aetna present a different picture. You pay the full negotiated price until your deductible is met. The negotiated rate Aetna pays for Trulicity is typically $700 to $900 per month, well below the $1,029 list price but still a significant expense during the deductible phase [7].

Lilly offers the Trulicity Savings Card for commercially insured patients. Eligible patients pay as little as $25 per prescription, with Lilly covering up to $150 per 30-day fill. This card works alongside Aetna commercial plans but cannot be used with Medicare, Medicaid, or other government-funded programs per federal anti-kickback statute requirements [8].

One important note: the savings card has an annual maximum benefit (typically $3,600 per calendar year). Patients using it should track their remaining benefit to avoid surprise costs mid-year.

Aetna Medicare Advantage and Part D Coverage

Aetna offers Medicare Advantage (Part C) and standalone Medicare Part D plans. Trulicity coverage on these plans differs from commercial coverage in several ways.

Medicare Part D plans from Aetna do cover Trulicity for type 2 diabetes. The drug is classified as a Part D medication because it is self-administered (injectable pen used at home). Prior authorization requirements apply, and the criteria mirror the commercial plan requirements: documented type 2 diabetes, metformin trial or contraindication, and supporting lab work [9].

Cost-sharing under Medicare Part D follows the standard benefit structure. During the initial coverage phase, you pay your plan's copay or coinsurance for Tier 3 or Tier 4 drugs. Once you hit the coverage gap (the "donut hole" threshold was $5 to 030 in total drug costs for 2025), you pay 25% of the drug's cost thanks to the Inflation Reduction Act provisions that closed the coverage gap [10]. The Inflation Reduction Act also capped total out-of-pocket Part D spending at $2,000 per year starting in 2025. This cap is significant for Trulicity users because a single GLP-1 RA can consume a large portion of that annual limit.

The Lilly Savings Card cannot be used with Medicare Part D plans. Medicare beneficiaries should ask their prescriber about Lilly's Patient Assistance Program (Lilly Cares), which provides free medication to qualifying low-income patients.

Trulicity vs. Other GLP-1s on Aetna Formularies

Aetna covers multiple GLP-1 receptor agonists, and the preferred agent can change year to year. Understanding where Trulicity sits relative to alternatives helps you and your prescriber choose the most cost-effective option.

As of 2025-2026 plan years, Aetna formularies commonly include Ozempic (semaglutide), Trulicity (dulaglutide), Victoza (liraglutide), Mounjaro (tirzepatide, a dual GIP/GLP-1 agonist), and Rybelsus (oral semaglutide). Tier placement varies. On some Aetna plans, Ozempic holds preferred status over Trulicity. On others, Trulicity is preferred [11].

From a clinical perspective, the choice between GLP-1 RAs involves weighing efficacy data. The SUSTAIN 7 trial (N=1,201) compared semaglutide 0.5 mg and 1.0 mg against dulaglutide 0.75 mg and 1.5 mg. Semaglutide produced greater HbA1c reductions (1.5% vs. 1.1% at the higher doses) and more weight loss (6.5 kg vs. 3.0 kg) over 40 weeks [12]. These efficacy differences may matter clinically, but insurance coverage often drives the initial choice.

If Aetna's formulary prefers Ozempic over Trulicity (or vice versa), your prescriber can request a formulary exception if there is a clinical reason for the non-preferred agent. Documented allergy, prior adverse reaction, or treatment failure with the preferred drug all qualify as valid exception reasons.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "The best GLP-1 receptor agonist for any individual patient is the one they can access, afford, and adhere to consistently" [2]. This practical reality means that formulary status and cost often matter as much as head-to-head trial data.

What to Do If Aetna Denies Trulicity Coverage

A denial is not the end. Aetna members have appeal rights under the Affordable Care Act's external review provisions, and a significant percentage of GLP-1 denials are overturned on appeal [13].

The appeals process has three levels. First, an internal appeal to Aetna (must be filed within 180 days of the denial). Aetna assigns a different reviewer who was not involved in the original decision. This internal appeal is decided within 30 days for non-urgent requests. Second, if the internal appeal is denied, you can request an external review by an independent review organization (IRO). The IRO's decision is binding on Aetna. Third, you can file a complaint with your state's Department of Insurance if you believe the denial violates state coverage mandates.

To strengthen an appeal, include the following: a letter of medical necessity from the prescriber, relevant lab results (HbA1c, fasting glucose, renal function if CKD is present), documentation of prior medication trials and failures, citations from ADA Standards of Care or Endocrine Society guidelines supporting GLP-1 RA use, and the REWIND trial data if cardiovascular risk reduction is a treatment goal [5].

Peer-to-peer review is another option. Your prescriber can request a phone call with Aetna's medical director to discuss the case directly. These conversations often resolve denials faster than written appeals.

Trulicity for Weight Management: Does Aetna Cover Off-Label Use?

Trulicity is FDA-approved for type 2 diabetes and cardiovascular risk reduction. It is not approved for weight management in patients without diabetes. This distinction matters for coverage.

Aetna generally does not cover Trulicity for weight loss alone. The FDA's approved indications for dulaglutide are limited to glycemic control in type 2 diabetes and reduction of MACE in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors [14]. Off-label prescribing for weight management would require the prescriber to submit a compelling case, and approvals for this indication are rare with any insurer.

For patients seeking GLP-1-based weight management through Aetna, the FDA-approved options are semaglutide 2.4 mg (Wegovy) and liraglutide 3.0 mg (Saxenda). Aetna's coverage for these weight-management-specific drugs varies significantly by plan. Many Aetna employer plans exclude anti-obesity medications entirely, while some include them with strict criteria (BMI 30 or greater, or BMI 27 or greater with at least one weight-related comorbidity) [15].

The STEP 1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo, establishing the evidence base for GLP-1 RA use in obesity [16]. If weight management is your primary goal, discuss Wegovy or tirzepatide (Zepbound) with your prescriber rather than seeking off-label Trulicity coverage.

How to Check Your Specific Aetna Plan's Trulicity Coverage

General guidance only goes so far. Your actual coverage depends on your specific plan. Here is how to verify it.

Log in to the Aetna member portal at aetna.com and use the "Find a Medication" tool. Enter "Trulicity" or "dulaglutide." The tool will display your plan's tier placement, prior authorization requirements, step therapy requirements, quantity limits, and estimated cost. You can also call Aetna's pharmacy benefits line (the number on the back of your ID card) and ask specifically: "Is Trulicity on my formulary, what tier is it on, and what are the PA criteria?"

Your prescriber's office can run a real-time benefit check (RTBC) through their electronic health record system. This electronic query returns your exact copay or coinsurance for Trulicity at a specific pharmacy before the prescription is even sent. RTBC adoption has grown substantially; the Centers for Medicare and Medicaid Services required all Part D plans to support RTBC by January 2023 [17].

Ask your pharmacist to run a test claim if you want a precise dollar amount before committing to the fill. The pharmacist can process the claim, see the adjudicated price, and then reverse it if you decide not to pick up the medication.